Literature DB >> 25333756

Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study.

Emmi Suomela1, Mervi Oikonen, Johanna Virtanen, Riitta Parkkola, Eero Jokinen, Tomi Laitinen, Nina Hutri-Kähönen, Mika Kähönen, Terho Lehtimäki, Leena Taittonen, Päivi Tossavainen, Antti Jula, Britt-Marie Loo, Vera Mikkilä, Zobair Younossi, Jorma S A Viikari, Markus Juonala, Olli T Raitakari.   

Abstract

BACKGROUND AND AIMS: Fatty liver may have different determinants in normal-weight and in obese individuals. We measured factors associated with fatty liver in 863 normal-weight (BMI < 25) and 1135 overweight/obese (BMI ≥ 25) young and middle-aged adults (45% male, age 34-49 years) in the population-based Cardiovascular Risk in Young Finns Study. METHODS AND
RESULTS: The prevalence of fatty liver detected with ultrasound was 29% in overweight/obese and 5% in normal-weight participants. In overweight/obese, the independent correlates were waist circumference (odds ratio for 1 standard deviation increase = 3.78), alanine transaminase (2.11), BMI (2.00), male sex (1.74), triglycerides (1.44), systolic blood pressure (1.31), fasting insulin (1.23), and physical activity (0.76). In normal weight, the independent correlates included alanine transaminase (3.05), smoking (2.56), systolic blood pressure (1.54), and alcohol intake (1.41). In normal-weight participants, the associations with fatty liver were stronger for alcohol intake and smoking, and weaker for triglycerides, than in overweight/obese participants (P for interaction < 0.05).
CONCLUSION: Prevalence of fatty liver was 29% in overweight/obese and 5% in normal-weight adults. Differences in factors associated with fatty liver were seen between these two groups: alcohol intake and smoking were more strongly and triglycerides more weakly associated in normal-weight than in overweight/obese participants.

Entities:  

Keywords:  Cohort studies; epidemiologic factors; fatty liver; normal body weight; overweight; prevalence

Mesh:

Substances:

Year:  2014        PMID: 25333756     DOI: 10.3109/07853890.2014.966752

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  14 in total

1.  Indicators of fetal growth and adult liver enzymes: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study.

Authors:  E W Harville; W Chen; L Bazzano; M Oikonen; N Hutri-Kähönen; O Raitakari
Journal:  J Dev Orig Health Dis       Date:  2016-12-06       Impact factor: 2.401

2.  Can Baseline Characteristics be Used to Predict Liver Disease Outcomes in Pediatric Nonalcoholic Fatty Liver Disease?

Authors:  Sarah Orkin; Toshifumi Yodoshi; Qin Sun; Lin Fei; Syeda Meryum; Ana Catalina Arce-Clachar; Kristin Bramlage; Andrew F Beck; Marialena Mouzaki
Journal:  Obesity (Silver Spring)       Date:  2020-11-13       Impact factor: 9.298

3.  Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study.

Authors:  Emma Raitoharju; Ilkka Seppälä; Leo-Pekka Lyytikäinen; Jorma Viikari; Mika Ala-Korpela; Pasi Soininen; Antti J Kangas; Melanie Waldenberger; Norman Klopp; Thomas Illig; Jaana Leiviskä; Britt-Marie Loo; Niku Oksala; Mika Kähönen; Nina Hutri-Kähönen; Reijo Laaksonen; Olli Raitakari; Terho Lehtimäki
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

4.  Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study.

Authors:  Jari E Kaikkonen; Peter Würtz; Emmi Suomela; Miia Lehtovirta; Antti J Kangas; Antti Jula; Vera Mikkilä; Jorma S A Viikari; Markus Juonala; Tapani Rönnemaa; Nina Hutri-Kähönen; Mika Kähönen; Terho Lehtimäki; Pasi Soininen; Mika Ala-Korpela; Olli T Raitakari
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

5.  Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort.

Authors:  Eline H van den Berg; Marzyeh Amini; Tim C M A Schreuder; Robin P F Dullaart; Klaas Nico Faber; Behrooz Z Alizadeh; Hans Blokzijl
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  Association of alcohol consumption with prevalence of fatty liver after adjustment for dietary patterns: Cross-sectional analysis of Japanese middle-aged adults.

Authors:  Ryoko Tajima; Fumiaki Imamura; Takeshi Kimura; Satomi Kobayashi; Katsunori Masuda; Kaoruko Iida
Journal:  Clin Nutr       Date:  2019-07-26       Impact factor: 7.324

7.  Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study.

Authors:  Kyung Eun Yun; Ga Eun Nam; Jisun Lim; Hye Soon Park; Yoosoo Chang; Hyun-Suk Jung; Chan-Won Kim; Byung-Joon Ko; Eun Chul Chung; Hocheol Shin; Seungho Ryu
Journal:  PLoS One       Date:  2016-07-15       Impact factor: 3.240

Review 8.  Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis.

Authors:  Michael Roerecke; Radu Nanau; Jürgen Rehm; Manuela Neuman
Journal:  EBioMedicine       Date:  2016-04-20       Impact factor: 8.143

9.  NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.

Authors:  Eeva Sliz; Sylvain Sebert; Peter Würtz; Antti J Kangas; Pasi Soininen; Terho Lehtimäki; Mika Kähönen; Jorma Viikari; Minna Männikkö; Mika Ala-Korpela; Olli T Raitakari; Johannes Kettunen
Journal:  Hum Mol Genet       Date:  2018-06-15       Impact factor: 6.150

10.  Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study.

Authors:  Francesco Giuseppe Foschi; Giorgio Bedogni; Marco Domenicali; Pierluigi Giacomoni; Anna Chiara Dall'Aglio; Francesca Dazzani; Arianna Lanzi; Fabio Conti; Sara Savini; Gaia Saini; Mauro Bernardi; Pietro Andreone; Amalia Gastaldelli; Andrea Casadei Gardini; Claudio Tiribelli; Stefano Bellentani; Giuseppe Francesco Stefanini
Journal:  BMC Gastroenterol       Date:  2018-11-28       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.